[Federal Register Volume 89, Number 103 (Tuesday, May 28, 2024)]
[Notices]
[Page 46148]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11604]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of The Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Novel and 
Exceptional Technology and Research Advisory Committee.
    The meeting will be held as a virtual meeting and will be open to 
the public as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting should notify the Contact Person listed below in 
advance of the meeting. The meeting will be videocast and can be 
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).

    Name of Committee: Novel and Exceptional Technology and Research 
Advisory Committee.
    Date: June 17, 2024.
    Time: 11:30 a.m. to 1:00 p.m.
    Agenda: The Novel and Exceptional Technology and Research 
Advisory Committee (NExTRAC) will receive an update from the Working 
Group on Engaging the Public as Partners in Clinical Research and 
discuss the next steps regarding the current charge to the 
committee, delivered in August 2023.
    Place: National Institutes of Health, 6705 Rockledge Drive, 
Suite 630, Bethesda, MD 20892 (Virtual Meeting).
    This meeting is a virtual meeting and can be accessed at: 
https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4/).
    Contact Person: Jessica Tucker, Ph.D., Acting Deputy Director, 
Office of Science Policy, National Institutes of Health, 6705 
Rockledge Drive, Suite 630, Bethesda, MD 20892, 301-496-9838, 
[email protected].
    Any interested person may file written comments by forwarding 
the statement to the Contact Person listed on this notice at least 
two business days prior to the meeting date. The statement should 
include the name, address, telephone number and when applicable, the 
business or professional affiliation of the interested person. Other 
than name and contact information, please do not include any 
personally identifiable information or any information that you do 
not wish to make public. Proprietary, classified, confidential, or 
sensitive information should not be included in your comments. 
Please note that any comments NIH receives may be posted unredacted 
to the Office of Science Policy website.
    Information is also available on the NIH Office of Science 
Policy website: https://osp.od.nih.gov/policies/novel-and-exceptional-technology-and-research-advisory-committee-nextrac#tab4, 
where an agenda, link to the webcast meeting, and any additional 
information for the meeting will be posted when available. Materials 
for this meeting will be posted prior to the meeting. Please check 
this website for updates.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: May 21, 2024.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-11604 Filed 5-24-24; 8:45 am]
BILLING CODE 4140-01-P